Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
After finding a protein that smoking affects to drive head and neck cancer, investigators hope manipulating it will prove beneficial.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
Building on this discovery, researchers have designed a new treatment that showed promise in a study of mice.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
Could new cancer drugs restore immune responses against HIV?
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
A genomic sequencing program revealed a genetic mutation that was able to be successfully treated with a checkpoint inhibitor.
An early study conducted among those with indolent lymphoma showed promising results.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.